ABSTRACT
Complex diseases, including cancer, are highly heterogeneous, and large molecular datasets are increasingly part of describing an individual’s unique experience. Gene expression is particularly attractive because it captures genetic, epigenetic and environmental consequences. SPECTRA is an approach to describe variation in a transcriptome as a set of unsupervised quantitative variables. Spectra variables provide a deep dive into the transcriptome, representing both large (prominent, high-level) and small (deeper, more subtle) sources of variance. Spectra variables are ideal for modeling alongside other variables for any outcome of interest. Each spectrum can also be considered a phenotypic trait, providing new avenues for disease characterization or to explore disease risk. We applied the SPECTRA approach to multiple myeloma (MM), the second most common blood cancer. Using RNA sequencing from malignant CD138+ cells, we derived 39 spectra in 767 patients from the MMRF CoMMpass study. We included spectra in prediction models for several clinical endpoints, compared to established expression-based risk scores, and used descriptive modeling to identify associations with patient characteristics. Spectra-based risk scores added predictive value beyond established clinical risk factors and other expression-based risk scores for overall survival, progression-free survival, and time to first-line treatment failure. We identified significant associations between CD138+ spectra and tumor cytogenetics, race, gender, and age at diagnosis. The SPECTRA approach provides quantitative measures of transcriptome variation to deeply profile tumors. This framework more comprehensively represents signals in the transcriptome and offers greater flexibility to model clinical outcomes and characteristics.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
Research reported in this publication was supported by the National Cancer Institute (Award Numbers F99CA234943, K00CA234943, and P30CA042014-29S9), the National Center for Advancing Translational Sciences (Award Number UL1TR002538), the National Library of Medicine (Award Number T15LM007124) of the National Institutes of Health. The content is solely the responsibility of the authors and does not necessarily represent the official views of the National Institutes of Health.
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Publicly available RNAseq data were used in this project from the Multiple Myeloma Research Foundation (MMRF) CoMMpass trial (NCT145429). To be eligible, a patient must have read, understood and signed informed consent. RNAseq data was downloaded directly from the MMRF Researcher Gateway (https://research.themmrf.org) after creating an account. Permission was also obtained to access these data via dbGaP under accessions phs000348.v2.p1 and phs000748.v4.p3.
All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.
Yes
The Chan Zuckerberg Initiative, Cold Spring Harbor Laboratory, the Sergey Brin Family Foundation, California Institute of Technology, Centre National de la Recherche Scientifique, Fred Hutchinson Cancer Center, Imperial College London, Massachusetts Institute of Technology, Stanford University, University of Washington, and Vrije Universiteit Amsterdam.
Subject Area
Reviews and Context
0
Comment
0
TRIP Peer Reviews
0
Community Reviews
0
Automated Services
0
Blogs/Media
Author Videos